- Vertex gains exclusive global rights to develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases.
- WuXi Biologics will receive upfront, development, regulatory, and sales milestone payments, plus royalties.
- WuXi Biologics will provide contract research and development services for next-generation TCEs.
Agreement Overview
WuXi Biologics has signed a license and research service agreement with Vertex Pharmaceuticals for a trispecific T-cell Engager (TCE) aimed at treating B-cell mediated autoimmune diseases. Vertex will have exclusive global rights to develop and commercialize this preclinical stage TCE.
Financial Terms
WuXi Biologics will receive an upfront payment and is eligible for development, regulatory, and sales milestone payments, along with royalty payments. The agreement also includes contract research and development services for novel next-generation TCEs.
Statements from Executives
Dr. Chris Chen, CEO of WuXi Biologics, emphasized the collaboration's role in supporting Vertex's efforts to develop transformative medicines. Mark Bunnage, Chief Scientific Officer at Vertex, highlighted the agreement as a tool to accelerate the advancement of new medicines.
